Herpes simplex virus 1 targets IRF7 via ICP0 to limit type I IFN induction. 2020

David Shahnazaryan, and Rana Khalil, and Claire Wynne, and Caroline A Jefferies, and Joan Ní Gabhann-Dromgoole, and Conor C Murphy
Department of Ophthalmology, Royal College of Surgeons in Ireland, Dublin 2, Ireland.

Herpes simplex keratitis (HSK), caused by herpes simplex virus type 1 (HSV-1) infection, is the commonest cause of infectious blindness in the developed world. Following infection the virus is initially suspended in the tear film, where it encounters a multi-pronged immune response comprising enzymes, complement, immunoglobulins and crucially, a range of anti-viral and pro-inflammatory cytokines. However, given that HSV-1 can overcome innate immune responses to establish lifelong latency throughout a susceptible individual's lifetime, there is significant interest in understanding the mechanisms employed by HSV-1 to downregulate the anti-viral type I interferon (IFN) mediated immune responses. This study aimed to investigate the interactions between infected cell protein (ICP)0 and key elements of the IFN pathway to identify possible novel targets that contribute to viral immune evasion. Reporter gene assays demonstrated the ability of ICP0 to inhibit type I IFN activity downstream of pathogen recognition receptors (PRRs) which are known to be involved in host antiviral defences. Further experiments identified interferon regulatory factor (IRF)7, a driver of type I IFN, as a potential target for ICP0. These findings increase our understanding of the pathogenesis of HSK and suggest IRF7 as a potential therapeutic target.

UI MeSH Term Description Entries
D007370 Interferon Type I Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA). Interferons Type I,Type I Interferon,Type I Interferons,Interferon, Type I,Interferons, Type I
D011401 Promoter Regions, Genetic DNA sequences which are recognized (directly or indirectly) and bound by a DNA-dependent RNA polymerase during the initiation of transcription. Highly conserved sequences within the promoter include the Pribnow box in bacteria and the TATA BOX in eukaryotes. rRNA Promoter,Early Promoters, Genetic,Late Promoters, Genetic,Middle Promoters, Genetic,Promoter Regions,Promoter, Genetic,Promotor Regions,Promotor, Genetic,Pseudopromoter, Genetic,Early Promoter, Genetic,Genetic Late Promoter,Genetic Middle Promoters,Genetic Promoter,Genetic Promoter Region,Genetic Promoter Regions,Genetic Promoters,Genetic Promotor,Genetic Promotors,Genetic Pseudopromoter,Genetic Pseudopromoters,Late Promoter, Genetic,Middle Promoter, Genetic,Promoter Region,Promoter Region, Genetic,Promoter, Genetic Early,Promoter, rRNA,Promoters, Genetic,Promoters, Genetic Middle,Promoters, rRNA,Promotor Region,Promotors, Genetic,Pseudopromoters, Genetic,Region, Genetic Promoter,Region, Promoter,Region, Promotor,Regions, Genetic Promoter,Regions, Promoter,Regions, Promotor,rRNA Promoters
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D005786 Gene Expression Regulation Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control (induction or repression) of gene action at the level of transcription or translation. Gene Action Regulation,Regulation of Gene Expression,Expression Regulation, Gene,Regulation, Gene Action,Regulation, Gene Expression
D006561 Herpes Simplex A group of acute infections caused by herpes simplex virus type 1 or type 2 that is characterized by the development of one or more small fluid-filled vesicles with a raised erythematous base on the skin or mucous membrane. It occurs as a primary infection or recurs due to a reactivation of a latent infection. (Dorland, 27th ed.) Herpes Simplex Virus Infection
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001483 Base Sequence The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence. DNA Sequence,Nucleotide Sequence,RNA Sequence,DNA Sequences,Base Sequences,Nucleotide Sequences,RNA Sequences,Sequence, Base,Sequence, DNA,Sequence, Nucleotide,Sequence, RNA,Sequences, Base,Sequences, DNA,Sequences, Nucleotide,Sequences, RNA
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D015533 Transcriptional Activation Processes that stimulate the GENETIC TRANSCRIPTION of a gene or set of genes. Gene Activation,Genetic Induction,Transactivation,Induction, Genetic,Trans-Activation, Genetic,Transcription Activation,Activation, Gene,Activation, Transcription,Activation, Transcriptional,Genetic Trans-Activation,Trans Activation, Genetic
D016899 Interferon-beta One of the type I interferons produced by fibroblasts in response to stimulation by live or inactivated virus or by double-stranded RNA. It is a cytokine with antiviral, antiproliferative, and immunomodulating activity. Interferon, Fibroblast,beta-Interferon,Fiblaferon,Interferon, beta,Interferon, beta-1,Interferon-beta1,beta-1 Interferon,Fibroblast Interferon,Interferon beta,Interferon beta1,Interferon, beta 1,beta 1 Interferon,beta Interferon

Related Publications

David Shahnazaryan, and Rana Khalil, and Claire Wynne, and Caroline A Jefferies, and Joan Ní Gabhann-Dromgoole, and Conor C Murphy
December 2006, Virologie (Montrouge, France),
David Shahnazaryan, and Rana Khalil, and Claire Wynne, and Caroline A Jefferies, and Joan Ní Gabhann-Dromgoole, and Conor C Murphy
January 2005, Journal of virology,
David Shahnazaryan, and Rana Khalil, and Claire Wynne, and Caroline A Jefferies, and Joan Ní Gabhann-Dromgoole, and Conor C Murphy
January 2021, The Journal of clinical investigation,
David Shahnazaryan, and Rana Khalil, and Claire Wynne, and Caroline A Jefferies, and Joan Ní Gabhann-Dromgoole, and Conor C Murphy
May 2010, Journal of virology,
David Shahnazaryan, and Rana Khalil, and Claire Wynne, and Caroline A Jefferies, and Joan Ní Gabhann-Dromgoole, and Conor C Murphy
July 2006, Journal of virology,
David Shahnazaryan, and Rana Khalil, and Claire Wynne, and Caroline A Jefferies, and Joan Ní Gabhann-Dromgoole, and Conor C Murphy
January 1991, Virology,
David Shahnazaryan, and Rana Khalil, and Claire Wynne, and Caroline A Jefferies, and Joan Ní Gabhann-Dromgoole, and Conor C Murphy
April 2011, Journal of virology,
David Shahnazaryan, and Rana Khalil, and Claire Wynne, and Caroline A Jefferies, and Joan Ní Gabhann-Dromgoole, and Conor C Murphy
April 2014, Cell host & microbe,
David Shahnazaryan, and Rana Khalil, and Claire Wynne, and Caroline A Jefferies, and Joan Ní Gabhann-Dromgoole, and Conor C Murphy
November 2000, Journal of virology,
David Shahnazaryan, and Rana Khalil, and Claire Wynne, and Caroline A Jefferies, and Joan Ní Gabhann-Dromgoole, and Conor C Murphy
January 2005, Methods in molecular medicine,
Copied contents to your clipboard!